Categories
Change Password!
Reset Password!
Physicians should consider Zavegepant intranasal spray as a valuable addition to their migraine management toolkit, but be wary of side effects like dysgeusia.
A recent review published in the ‘Expert Review of Neurotherapeutics’ journal suggested intranasal Zavegepant to be effective, safe, and well-tolerated, particularly for those with sudden-onset migraine attacks, nausea or vomiting, and patients with a higher cardiovascular risk. While dysgeusia (altered taste) was a commonly reported side effect, additional research is needed to enhance understanding and develop better management strategies for this concern.
Migraine is a widespread neurological condition that produces significant disability, and despite medical advancements, many patients still battle with inadequate treatment options. Guy Greco and Teshamae Monteith aimed to assess the effectiveness, safety, and outcomes of the latest studies on intranasal Zavegepant for the acute treatment of migraines, both with and without aura. Researchers searched PubMed using terms such as 'zavegepant,' 'Zavzpret,' 'migraine,' 'calcitonin gene-related peptide,' and 'CGRP receptor antagonists.'
Findings from Phase 1, Phase 2/3, and Phase 3 randomized, double-blind, placebo-controlled trials that examined the efficacy of intranasal Zavegepant in treating acute migraine episodes were underlined. It should be noted that although direct comparisons with other migraine-specific therapies are limited, treatment decisions should be tailored to individual patients, considering the unique characteristics of their migraine attacks.
Expert Review of Neurotherapeutics
Intranasal Zavegepant for the acute treatment of migraine
Guy Greco, Teshamae Monteith
Comments (0)